Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps

Overview

Journal Nutrients

Date 2024 Sep 14

PMID 39275297

Authors

Michael Habenbacher

Ulrich Moser

Ahmed Abaira

Peter Valentin Tomazic

Peter Kiss

Clemens Holzmeister

Jakob Pock

Katharina Walla

Angelika Lang

Alexandros Andrianakis

Affiliations

Soon will be listed here.

Abstract

Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts quality of life and often presents therapeutic challenges, with biologics like dupilumab showing promise in managing severe, uncontrolled cases. The aim of this study was to assess the influence of overweight on the effectiveness of dupilumab in patients with uncontrolled CRSwNP. This retrospective study analyzed treatment outcomes of 75 CRSwNP patients receiving dupilumab, categorizing them into underweight/normal-weight (BMI ≤ 24.9 kg/m) and overweight/obese (BMI ≥ 25 kg/m) groups. Outcome measures included changes in nasal polyp score (NPS) and sinonasal outcome test (SNOT-22) scores. Results demonstrated that the underweight/normal-weight group experienced significantly greater improvements in NPS and a higher rate of total NPS improvement compared to the overweight/obese group. While SNOT-22 scores improved in both groups, no significant differences were observed. Among patients with comorbid asthma, the underweight/normal-weight subgroup also showed significantly better outcomes, including greater reductions in both NPS and SNOT-22 scores. Multiple regression analysis identified BMI as an independent prognostic factor for NPS outcomes. The findings suggest that overweight/obesity adversely affects the response to dupilumab in CRSwNP, emphasizing the need for personalized treatment strategies considering BMI.

References

Chen W, Bai Y, Fang P, Chen J, Wang X, Li Y . Body mass indexâ€™s effect on CRSwNP extends to pathological endotype and recurrence. Rhinology. 2024; 62(3):370-382. DOI: 10.4193/Rhin23.402. View

Fokkens W, Viskens A, Backer V, Conti D, De Corso E, Gevaert P . EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023; 61(3):194-202. DOI: 10.4193/Rhin22.489. View

De Corso E, Montuori C, Baroni S, Mastrapasqua R, Porru D, DAuria L . Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study. Eur Arch Otorhinolaryngol. 2023; 281(5):2429-2440. DOI: 10.1007/s00405-023-08417-8. View

Yao Y, Zeng M, Liu Z . Revisiting Asian chronic rhinosinusitis in the era of type 2 biologics. Clin Exp Allergy. 2021; 52(2):231-243. DOI: 10.1111/cea.14065. View

Toki S, Goleniewska K, Reiss S, Zhang J, Bloodworth M, Stier M . Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell cytokine production in vivo. J Allergy Clin Immunol. 2018; 142(5):1515-1528.e8. PMC: 9639650. DOI: 10.1016/j.jaci.2017.11.043. View

Reale M, Licci G, Orlando P, Matucci A, Trabalzini F, Maggiore G . Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature. Eur Arch Otorhinolaryngol. 2024; 281(10):5023-5031. DOI: 10.1007/s00405-024-08725-7. View

Bachert C, Bhattacharyya N, Desrosiers M, Khan A . Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps. J Asthma Allergy. 2021; 14:127-134. PMC: 7886239. DOI: 10.2147/JAA.S290424. View

Bachert C, Han J, Wagenmann M, Hosemann W, Lee S, Backer V . EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. J Allergy Clin Immunol. 2020; 147(1):29-36. DOI: 10.1016/j.jaci.2020.11.013. View

Tashiro H, Kurihara Y, Kuwahara Y, Takahashi K . Impact of obesity in asthma: Possible future therapies. Allergol Int. 2023; 73(1):48-57. DOI: 10.1016/j.alit.2023.08.007. View

10.

. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017; 390(10113):2627-2642. PMC: 5735219. DOI: 10.1016/S0140-6736(17)32129-3. View

11.

Hoying D, Miller K, Tanzo J, Kim J, Bena J, Burguera B . Evaluating the Association of Obesity and Chronic Rhinosinusitis: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2023; 170(3):708-723. DOI: 10.1002/ohn.612. View

12.

Bhattacharyya N, Villeneuve S, Joish V, Amand C, Mannent L, Amin N . Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps. Laryngoscope. 2019; 129(9):1969-1975. PMC: 6767455. DOI: 10.1002/lary.27852. View

13.

Matucci A, Micheletto C, Vultaggio A . Severe Asthma and Biologics: Managing Complex Patients. J Investig Allergol Clin Immunol. 2022; 33(3):168-178. DOI: 10.18176/jiaci.0856. View

14.

Wang A, Zhou Y, Luo Y, Gao Y, Chen J, Li W . High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis. Front Immunol. 2023; 14:1160710. PMC: 10157040. DOI: 10.3389/fimmu.2023.1160710. View

15.

Yang N, Waytz A, Soler Z, Overdevest J, Gudis D . The effects of priming on rhinologic patient reported outcome measures: a randomized controlled trial. Rhinology. 2023; 62(1):71-81. DOI: 10.4193/Rhin23.172. View

16.

Fokkens W, Lund V, Hopkins C, Hellings P, Kern R, Reitsma S . European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020; 58(Suppl S29):1-464. DOI: 10.4193/Rhin20.600. View

17.

Phillips K, Sedaghat A . Depression and Anxiety: Considerations for Interpretation of the SNOT-22 (22-Item Sinonasal Outcome Test). Otolaryngol Head Neck Surg. 2021; 166(5):985-992. DOI: 10.1177/01945998211059732. View

18.

Garg D, Que L, Ingram J . Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity. Front Pharmacol. 2024; 14:1315540. PMC: 10800376. DOI: 10.3389/fphar.2023.1315540. View

19.

DeConde A, Mace J, Levy J, Rudmik L, Alt J, Smith T . Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2016; 127(3):550-555. PMC: 5321782. DOI: 10.1002/lary.26391. View

20.

Xie S, Jiang S, Fan R, Gao K, Shui J, Wang F . Elevated body mass index increased the risk of recurrence in Chinese patients with chronic rhinosinusitis. Am J Otolaryngol. 2023; 44(4):103841. DOI: 10.1016/j.amjoto.2023.103841. View